Advertisement

Prevention of Lesion Recurrence in Endovascular Devices

  • Adrienne L. Rochier
  • Bauer E. Sumpio
Chapter

Abstract

Although the use of autogenous bypass grafts is generally considered the optimal technique of augmenting perfusion to poorly perfused limbs, many patients do not have adequate conduit or are not at suitable risk for invasive surgery. One of the innovations over the last few decades has been the development of techniques to restore flow through endovascular methods such as angioplasty and vascular stents. Intra-arterial stent placement to treat atherosclerotic obstruction was proposed by Dotter and Judkins in 1964. The first use of percutaneously implanted stents in human arteries was the placement of the Wallstent in coronary, iliac, and femoral arteries in 1987 [1]. Shortly thereafter, favorable results in a multicenter trial with the Palmaz stent in iliac arteries were reported [2]. Stents were approved by the US Food and Drug Administration for use in iliac arteries in the United States in 1991.

Keywords

Vascular Endothelial Growth Factor Intimal Hyperplasia Smooth Muscle Cell Proliferation Lesion Recurrence Neointimal Formation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L: Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty, N Engl J Med 316:701–706, 1987.PubMedCrossRefGoogle Scholar
  2. 2.
    Palmaz JC, Richter GM, Noeldge G et al.: Intraluminal stents in atherosclerotic iliac artery stenosis: preliminary report of a multicenter study, Radiology 168:727–731, 1988.Google Scholar
  3. 3.
    Pentecost MJ, Criqui MH, Dorros G et al.: Guidelines for peripheral percutaneous transluminal angioplasty of the abdominal aorta and lower extremity vessels: a statement for health professionals from a special writing group of the councils on cardiovascular radiology, arteriosclerosis, cardio-thoracic and vascular surgery, clinical cardiology, and epidemiology and prevention, the American heart association, Circ J 89:511–531, 1994.Google Scholar
  4. 4.
    Murphy TP, Ariaratnam NS, Carney WI, Marcaccio EJ, Slaiby JM, Soares GM, Kim HM: Aortoiliac insufficiency: long-term experience with stent placement for treatment, Radiology 231:243–249, 2004.PubMedCrossRefGoogle Scholar
  5. 5.
    Ivanovic V, McKusick MA, Johnson CM 3rd, Sabater EA, Andrews JC, Breen JF, Bjarnason H, Misra S, Stanson AW: Renal artery stent placement: complications at a single tertiary care center, J Vasc Intervent Radiol 14(2 Pt 1): 217–225, 2003.CrossRefGoogle Scholar
  6. 6.
    Henry M, Amor M, Henry I, Ethevenot G, Tzvetanov K, Courvoisier A, Mentre B, Chati Z: Stents in the treatment of renal artery stenosis: long-term follow-up, J Endovasc Surg 6(1):42–51, 1999.PubMedCrossRefGoogle Scholar
  7. 7.
    Cunningham LD, Conte MS: Lower-extremity arterial disease, Perspect Vasc Surg Endovasc Ther. 17(4):351–361, 2005.PubMedCrossRefGoogle Scholar
  8. 8.
    Trabattoni D, Bartorelli AL: Late occlusive in-stent restenosis of a bare-metal stent presenting with ST-elevation anterior MI: is restenosis better than a late stent thrombosis? Int J Cardiol 34:186–94, 2008.Google Scholar
  9. 9.
    Farb A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS, Virmani R: Pathology of acute and chronic coronary stenting in humans, Circ J 99:44–52, 1999.Google Scholar
  10. 10.
    Geary RL, Williams JK, Golden D, Brown DG, Benjamin ME, Adams MR: Time course of cellular proliferation, intimal hyperplasia, and remodeling following angioplasty in monkeys with established atherosclerosis, Arterioscler Thromb Vasc Biol 16:34–43, 1996.PubMedCrossRefGoogle Scholar
  11. 11.
    Borromeo JR, Sumpio BE: Strategies in preventing intimal hyperplasia. In Whittemore A, Bandyk D, Cronenwett J, Herrtzer N, White R, editors: Advances in vascular surgery, St. Louis, MO, 2002, Mosby, pp. 201–218.Google Scholar
  12. 12.
    Feldman LJ, Aguirre L, Ziol M, Bridou JP, Nevo N, Michel JB, Steg PG: Interleukin-10 inhibits intimal hyperplasia after angioplasty or stent implantation in hypercholesterolemic rabbits, Circ J 101:908–916, 2000.Google Scholar
  13. 13.
    Frangos S, Gahtan V, Sumpio BE: Localization of atherosclerosis: role of hemodynamics, Arch Surg 134:1142–1149, 1999.PubMedCrossRefGoogle Scholar
  14. 14.
    Kohler TR, Kirkman TR, Kraiss LW, Zierler BK, Clowes AW: Increased blood flow inhibits neointimal hyperplasia in endothelialized vascular grafts, Circ Res 69:1557–1565, 1991.PubMedGoogle Scholar
  15. 15.
    Steinthorsson G, Sumpio BE: Clinical and biological relevance of vein cuff anastomosis, Acta Chir Belg. 99:282–288, 1999.PubMedGoogle Scholar
  16. 16.
    Kohler TR, Clowes AW: Prevention of lesion recurrence in endovascular devices. In White RA, Fogarty, TJ, editors.: Peripheral Endovascular Interventions, ed. 2, New York, 1999, Springer-Verlag New York, Inc, 539–553.Google Scholar
  17. 17.
    Sumpio BE: Atherosclerosis: biological and surgical considerations, In Ascher E, Hollier L, Strandness DE, editors: Haimovici’s vascular surgery, ed. 5, Malden, MA, 2004, Blackwell Science, Inc, pp. 137–163.CrossRefGoogle Scholar
  18. 18.
    Pasterkamp G, de Kleijn DP, Borst C: Arterial remodeling in atherosclerosis, restenosis and after alteration of blood flow: potential mechanisms and clinical implications, Cardiovasc Res 45(4):843–852, 2000.PubMedCrossRefGoogle Scholar
  19. 19.
    Haruguchi H, Teraoka S: Intimal hyperplasia and hemodynamic factors in arterial bypass and arteriovenous grafts: a review, J Artif Organs. 6(4):227–235, 2003.PubMedCrossRefGoogle Scholar
  20. 20.
    Schwartz SM, de Blois D, O’Brien ER: The intima. Soil for atherosclerosis and restenosis, Circ Res 77(3):445–465, 1995.PubMedGoogle Scholar
  21. 21.
    Lindner V, Reidy MA: Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA, 88:3739–3743, 1991.PubMedCrossRefGoogle Scholar
  22. 22.
    22.Olson NE, Chao S, Lindner V, Reidy MA: Intimal smooth muscle cell proliferation after balloon catheter injury: the role of basic fibroblast growth factor, Am J Pathol 140:1017–1023, 1992.PubMedGoogle Scholar
  23. 23.
    Langille BL: Remodeling of developing and mature arteries: endothelium, smooth muscle, and matrix, J Cardiovasc Pharmacol 21(suppl 1):S11–S17, 1993.PubMedCrossRefGoogle Scholar
  24. 24.
    Fattori R, Piva T: Drug-eluting stents in vascular intervention, The Lancet 361(9353):247–249, 2003.CrossRefGoogle Scholar
  25. 25.
    Lafont A, Guzman LA, Whitlow PL, Goormastic M, Cornhill JF, Chisolm GM: Restenosis after experimental angioplasty. Intimal, medial, and adventitial changes associated with constrictive remodeling, Circ Res 76(6):996–1002, 1995.PubMedGoogle Scholar
  26. 26.
    Ryan ST, Koteliansky VE, Gotwals PJ, Lindner V: Transforming growth factor-beta-dependent events in vascular remodeling following arterial injury, J Vasc Res 40(1):37–46, 2003.PubMedCrossRefGoogle Scholar
  27. 27.
    Paszkowiak JJ, Maloney SP, Kudo FA, Muto A, Teso D, Rutland RC, Westvik TS, Pimiento JM, Tellides G, Sessa WC, Dardik A: Evidence supporting changes in Nogo-B levels as a marker of neointimal expansion but not adaptive arterial remodeling, Vascul Pharmacol 46(4):293–301, 2007.PubMedCrossRefGoogle Scholar
  28. 28.
    Assmus B, Walter DH, Lehmann R, Honold J, Martin H, Dimmeler S, Zeiher AM, Schächinger V: Intracoronary infusion of progenitor cells is not associated with aggravated restenosis development or atherosclerotic disease progression in patients with acute myocardial infarction, Eur Heart J 27(24):2989–2995, 2006.PubMedCrossRefGoogle Scholar
  29. 29.
    Hiatt BL, Ikeno F, Yeung AC, Carter AJ: Drug-eluting stents for the prevention of restenosis: in quest for the Holy Grail, Catheter Cardiovasc Interv 55(3):409–417, 2002.PubMedCrossRefGoogle Scholar
  30. 30.
    Serruys PW, Ormiston JA, Sianos G, Sousa JE, Grube E, den Heijer P, de Feyter P, Buszman P, Schömig A, Marco J, Polonski L, Thuesen L, Zeiher AM, Bett JH, Suttorp MJ, Glogar HD, Pitney M, Wilkins GT, Whitbourn R, Veldhof S, Miquel K, Johnson R, Coleman L, Virmani R: ACTION investigators. Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial, J Am Coll Cardiol 44(7):1363–1367, 2004.PubMedGoogle Scholar
  31. 31.
    Siablis D, Karnabatidis D, Katsanos K, Diamantopoulos A, Christeas N, Kagadis GC: Infrapopliteal application of paclitaxel-eluting stents for critical limb ischemia: midterm angiographic and clinical results, J Vasc Interv Radiol 18(11):1351–1361, 2007.PubMedCrossRefGoogle Scholar
  32. 32.
    Grube E, Siber MS, Hauptmann KE: Prospective, randomized, double-blind comparison of NIRx stents coated with paclitaxel in a polymer carrier in de-novo coronary lesions compared with uncoated controls, Circ J 104(suppl):II-463, 2001.Google Scholar
  33. 33.
    Hong MK, Mintz GS, Lee CW, Song JM, Han KH, Kang DH, Song JK, Kim JJ, Weissman NJ, Fearnot NE, Park SW, Park SJ: Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries a serial volumetric intravascular ultrasound analysis from the ASian Paclitaxel-Eluting Stent Clinical Trial (ASPECT), Circ J 107:517–520, 2003.CrossRefGoogle Scholar
  34. 34.
    Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwälder U, Beregi JP, Claussen CD, Oldenburg A, Scheller B, Speck U: Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg, N Engl J Med 358(7):689–699, 2008.PubMedCrossRefGoogle Scholar
  35. 35.
    Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM, Seixas AC, Staico R, Mattos LA, Sousa AG, Falotico R, Jaeger J, Popma JJ, Serruys PW: Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study, Circ J 103:192–195, 2001.Google Scholar
  36. 36.
    Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnàr F, Falotico R: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization, N Engl J Med 346(23):1773–1780, 2002.PubMedCrossRefGoogle Scholar
  37. 37.
    Teirstein PS, Kuntz RE: New frontiers in interventional cardiology. Circ J 104:2620–2626, 2001.CrossRefGoogle Scholar
  38. 38.
    Wolfram RM, Budinsky AC, Pokrajac B, Potter R, Minar E: Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five-year follow-up–prospective randomized study, Radiology 240(3):878–884, 2006.PubMedCrossRefGoogle Scholar
  39. 39.
    Hansrani M, Overbeck K, Smout J, Stansby G: Intravascular brachytherapy for peripheral vascular disease, Cochrane Database Syst Rev 4:CD003504, 2002.PubMedGoogle Scholar
  40. 40.
    Albiero R, Nishida T, Adamian M, Amato A, Vaghetti M, Corvaja N, Di Mario C, Colombo A: Edge restenosis after implantation of high activity 32P radioactive beta-emitting stents, Circ J 101:2454–2457, 2000.Google Scholar
  41. 41.
    Kim HS, Waksman R, Cottin Y, Kollum M, Bhargava B, Mehran R, Chan RC, Mintz GS: Edge stenosis and geographical miss following intracoronary gamma radiation therapy for in-stent restenosis, J Am Coll Cardiol 37:1026–1030, 2001.PubMedCrossRefGoogle Scholar
  42. 42.
    Albiero R, Adamian M, Kobayashi N: Short- and intermediate-term results of 32P radioactive (beta) β-emitting stent implantation in patients with coronary artery disease. The Milan dose-response study, Circ J 101:18–24, 2000.Google Scholar
  43. 43.
    Feldman LJ, Tahlil O, Steg G: Perspectives of arterial gene therapy for the prevention of restenosis, Cardiovasc Res 32(2):194–207, 1996.PubMedCrossRefGoogle Scholar
  44. 44.
    Nikol S, Huehns TY: Preclinical and clinical experience in vascular gene therapy: advantages over conservative/standard therapy, J Invasive Cardiol 13(4):333–338, 2001.PubMedGoogle Scholar
  45. 45.
    Brogi E, Wu T, Namiki A, Isner JM: Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only, Circ J 90:649–652, 1994.Google Scholar
  46. 46.
    Leong-Poi H, Kuliszewski MA, Lekas M, Sibbald M, Teichert-Kuliszewska K, Klibanov AL, Stewart DJ, Lindner JR: Therapeutic arteriogenesis by ultrasound-mediated VEGF165 plasmid gene delivery to chronically ischemic skeletal muscle. 2007 American Heart Association, Inc, Circ Res 101(3):295–303, 2007.PubMedCrossRefGoogle Scholar
  47. 47.
    Von der Leyen HE, Dzau VJ: Therapeutic potential of nitric oxide synthase gene manipulation, Circ J 103:2760–2765, 2001.Google Scholar
  48. 48.
    Urano T, Ito Y, Akao M, Sawa T, Miyata K, Tabata M, Morisada T, Hato T, Yano M, Kadomatsu T, Yasunaga K, Shibata R, Murohara T, Akaike T, Tanihara H, Suda T, Oike Y: Angiopoietin-related growth factor enhances blood flow via activation of the ERK1/2-eNOS-NO pathway in a mouse hind-limb ischemia model, Arterioscler Thromb Vasc Biol 28(5):827–834, 2008.PubMedCrossRefGoogle Scholar
  49. 49.
    Benest AV, Stone OA, Miller WH, Glover CP, Uney JB, Baker AH, Harper SJ, Bates DO: Arteriolar genesis and angiogenesis induced by endothelial nitric oxide synthase overexpression results in a mature vasculature, Arterioscler Thromb Vasc Biol 28(8):1462–1468, Published online May 22, 2008.PubMedCrossRefGoogle Scholar
  50. 50.
    Morishita R, Tomita N, Kaneda Y, Ogihara T: Molecular therapy to inhibit NFkappaB activation by transcription factor decoy oligonucleotides, Curr Opin Pharmacol 4(2):139–146, 2004.PubMedCrossRefGoogle Scholar
  51. 51.
    Conte MS, Bandyk DF, Clowes AW et al.: Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery, J Vasc Surg 43(4):742–751, 2006.PubMedCrossRefGoogle Scholar
  52. 52.
    Tatewaki H, Egashira K, Kimura S, Nishida T, Morita S, Tominaga R: Blockade of monocyte chemoattractant protein-1 by adenoviral gene transfer inhibits experimental vein graft neointimal formation, J Vasc Surg 45(6):1236–1243, 2007.PubMedCrossRefGoogle Scholar
  53. 53.
    Ohtani K, Usui M, Nakano K, Kohjimoto Y, Kitajima S, Hirouchi Y, Li XH, Kitamoto S, Takeshita A, Egashira K: Antimonocyte chemoattractant protein-1 gene therapy reduces experimental in-stent restenosis in hypercholesterolemic rabbits and monkeys, Gene Ther 11:1273–1282, 2004.PubMedCrossRefGoogle Scholar
  54. 54.
    Morka J, Krzemińska-Pakuła M, Drożdż J, Morka A: Factors affecting the progression of atherosclerosis in the coronary arteries, Kardiol Pol 65:1307–1311, 2007.PubMedGoogle Scholar
  55. 55.
    Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL, Kapadia SR, Nissen SE: Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis, JAMA 297(20):2197, 2007.CrossRefGoogle Scholar
  56. 56.
    56.Von Haehling S: Treatment options for endothelial dysfunction, Heart and Metab 22:22–28, 2004.Google Scholar
  57. 57.
    Williams JK, Sukhova GK, Herrington DM, Libby P: Pravastatin has cholesterol lowering effects on the artery wall of atherosclerotic monkeys, J Am Coll Cardiol 31(3):684–691, 1998.PubMedCrossRefGoogle Scholar
  58. 58.
    Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW: Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions, J Am Coll Cardiol 33(1):234–241, 1999.PubMedCrossRefGoogle Scholar
  59. 59.
    Bandoh T, Mitani H, Niihashi M, Kusumi Y, Ishikawa J, Kimura M, Totsuka T, Sakurai I, Hayashi S: Inhibitory effect of fluvastatin at doses insufficient to lower serum lipids on the catheter-induced thickening of intima in rabbit femoral artery, Eur J Pharmacol 315(1):37–42, 1996.PubMedCrossRefGoogle Scholar
  60. 60.
    Kamishirado H, Inoue T, Sakuma M, Tsuda T, Hayashi T, Takayanagi K, Node K: Effects of statins on restenosis after coronary stent implantation, Angiology 58(1):55–60, 2007.PubMedCrossRefGoogle Scholar
  61. 61.
    Chaer RA, Graham JA, Mureebe L: Platelet function and pharmacologic inhibition, Vasc Endovascular Surg 40(4):261–267, 2006.PubMedCrossRefGoogle Scholar
  62. 62.
    Dorffler-Melly J, Koopman MMW, Prins MH, Buller HR: Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment, Cochrane Database Syst Rev 1:CD002071, 2005.PubMedGoogle Scholar
  63. 63.
    Bhatt DL, Bertrand ME, Berger PB, L’Allier PL, Moussa I, Moses JW, Dangas G, Taniuchi M, Lasala JM, Holmes DR, Ellis SG, Topol EJ: Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting, J Am Coll Cardiol 39(1):9–14, 2002.PubMedCrossRefGoogle Scholar
  64. 64.
    Min PK, Jung JH, Ko YG, Choi D, Jang Y, Shim WH: Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantitative coronary angiography and volumetric intravascular ultrasound study, Circ J 71(11):1685–1690, 2007.PubMedCrossRefGoogle Scholar
  65. 65.
    Leon MB, Baim DS, Gordon P, Giambotolomei A, Williams D, Diver DD, Senerchia C, Fitzpatrick M, Popma J, Kuntz RE: Clinical and angiographic results from the Stent Anticoagulation Regimen Study (STARS), Circ J 94(suppl I):I-685, 1996.Google Scholar
  66. 66.
    Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H, Vrolix M, Missault L, Chierchia S, Casaccia M, Niccoli L, Oto A, White C, Webb-Peploe M, Van Belle E, McFadden EP: Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting, Circ J 98:1597–1603, 1998.Google Scholar
  67. 67.
    Greinacher A, Warkentin TE: The direct thrombin inhibitor hirudin, Thromb Haemost 99(5):819–829, 2008.PubMedGoogle Scholar
  68. 68.
    Chesebro JH, Webster MW, Zoldhelyi P, Roche PC, Badimon L, Badimon JJ: Antithrombotic therapy and progression of coronary artery disease: antiplatelet versus antithrombins, Circ J 86(suppl III):100–110, 1992.Google Scholar
  69. 69.
    Budoff M: Aged garlic extract retards progression of coronary artery calcification, J Nutr 136(3):741S–744S, 2006.PubMedGoogle Scholar
  70. 70.
    Faulkner KW, House AK, Castleden WM: The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease, Med J Aust 1:217–219, 1983.PubMedGoogle Scholar
  71. 71.
    Willigendael EM, Teijink JA, Bartelink ML, Peters RJ, Buller HR, Prins MH: Smoking and the patency of lower extremity bypass grafts: a meta-analysis, J Vasc Surg 42:67–74, 2005.PubMedCrossRefGoogle Scholar
  72. 72.
    Regensteiner JG, Steiner JF, Hiatt WR: Exercise training improves functional status in patients with peripheral arterial disease, J Vasc Surg 23:104–115, 1996.PubMedCrossRefGoogle Scholar
  73. 73.
    Leng GC, Fowler B, Ernst E: Exercise for intermittent claudication, Cochrane Database Syst Rev 2:CD000990, 2000.PubMedGoogle Scholar
  74. 74.
    Izquierdo-Porrera AM, Gardner AW, Powell CC, Katzel LI: Effects of exercise rehabilitation on cardiovascular risk factors in older patients with peripheral arterial occlusive disease, J Vasc Surg 31:670–677, 2000.PubMedCrossRefGoogle Scholar
  75. 75.
    Krause N, Brand RJ, Kaplan GA, Kauhanen J, Malla S, Tuomainen TP, Salonen JT: Occupational physical activity, energy expenditure and 11-year progression of carotid atherosclerosis, Scand J Work Environ Health 33(6):405–424, 2007.PubMedCrossRefGoogle Scholar
  76. 76.
    Pasa MB, Pereira AH, Júnior CC: Morphometric analysis of intimal thickening secondary to stent placement in pig carotid arteries, Acta Cir Bras 23(2):165–172, 2008.PubMedCrossRefGoogle Scholar
  77. 77.
    Kalinowski M, Alfke H, Bergen S et al.: Comparative trial of local pharmacotherapy with L-arginine, r-hirudin, and molsidomine to reduce restenosis after balloon angioplasty of stenotic rabbit iliac arteries, Radiology 219:716–723, 2001.PubMedGoogle Scholar
  78. 78.
    Dobesh PP, Stacy ZA, Ansara AJ, Enders JM: Drug-eluting stents: a mechanical and pharmacologic approach to coronary artery disease, Pharmacotherapy 24(11):1554–1577, 2004.PubMedCrossRefGoogle Scholar
  79. 79.
    Garrett RH, Grisham CM: Structure of Nucleic Acids. In Biochemistry, ed. 2, Fort Worth, TX, 1999, Saunders College Publishing, pp. 356–394.Google Scholar
  80. 80.
    Wessely R, Schömig A, Kastrati A: Sirolimus and paclitaxel on polymer-based drug-eluting stents, J Am Coll Cardiol 47:708–714, 2006.PubMedCrossRefGoogle Scholar
  81. 81.
    Albiero R, Colombo A: European high-activity (32)P radioactive stent experience, J Invasive Cardiol 12(8):416–421, 2000.PubMedGoogle Scholar
  82. 82.
    Jain HV, Nör JE, Jackson TL: Modeling the VEGF-Bcl-2-CXCL8 pathway in intratumoral angiogenesis, Bull Math Biol 70:89–117, 2008.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Adrienne L. Rochier
    • 1
  • Bauer E. Sumpio
    • 1
  1. 1.Department of Vascular SurgeryYale University School of MedicineNew HavenUSA

Personalised recommendations